Popular equity categories lag in FY25; pharma schemes returned much more than the rest

April 1, 2025

The value of pharma schemes rose as investors shifted focus to drugmakers, considered defensive in uncertain times. As per data from Value Research the mid-cap category offered the highest return of 8.93%, followed by multi-caps which returned 7.88%.

More To Explore

Hugh Johnson warns: Market entering volatile, trendless phase amid tariff chaos

Hugh Johnson Economics suggests the market will be volatile and trendless, mirroring the 2018-2019 trade war. Proposed tariffs on Canada and Brazil could impact global

July 11, 2025

Meta Infotech shares list at 40% premium over IPO price on BSE SME platform

Meta Infotech debuted strongly on the BSE SME platform, listing at Rs 225, a 39.75% premium over its IPO price. The Rs 80.18 crore public

July 11, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003